Journal of
eISSN: 2373-633X
Submit manuscript...
Editorial Volume 1 Issue 3
Trojan horse, nanomedicine and oncology
Bruno De Lema Larre
Verify Captcha
Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.
Verify Captcha
Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.
High Complexity Foundation, Spain
Correspondence: De Lema Bruno, High Complexity Foundation, Pereira, Barcelona, Spain
Received: October 29, 2014 | Published: December 20, 2014
Citation: Larre BDL. Trojan horse, nanomedicine and oncology. J Cancer Prev Curr Res. 2014;1(4):103. DOI: 10.15406/jcpcr.2014.01.00020
Editorial
Our world is increasingly miniaturized. Nanotechnology helps this goal. The advancement of nanoscience is undeniable and there is talk that nanoscience will be the second industrial revolution. One of these resources is nanodrugs. These are nanoparticles that carry drugs to specific target cells. Research in this area is of special interest in oncology.
Nanodrug is designed as an element that must have as properties:
- Affect solely to the target cell in this case neoplastic cells,
- Not affect or destroy healthy cells,
- Not immunologically reactive therefore not arouse an immune reaction against nanoparticles.
Once the nanodrug comes to cancer cell, it is able to release its contents and meet the objective of destroying the tumor cell, although the theory is simple. Nanodrugs must overcome complex difficulties. First of all must be transported through the blood stream, they circumvent hepatic metabolism and renal excretion, as well as being "silent immune" and finally break through to the neoplastic cell to deposit their contents and destroy the tumor cell and no another. The idea is basically the Trojan horse (Figure 1). A structure apparently without destructive capacity, its interior contains the components necessary to do otherwise. Destroy a target. Doing it stealthily and unexpected. What it is clear that the oncology will not be equal when nanodrugs more frequent, yet, we finish building this Trojan horse.
Figure 1 Trojan horse.
Acknowledgments
None.
Conflicts of interest
Author declares there are no conflicts of interest.
©2014 Larre. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.